Search
News & Events
Improving the health and wellbeing of Aboriginal KidsThe Kids created history by surveying 1 in 6 indigenous children across the State and collecting information on just how this generation is travelling.
News & Events
A healthy start for you and your next bubPregnancy brings with it some level of risk. There is no getting around that. Of course, women want to do the best for their baby, but there is a risk.
News & Events
Video: Vinka Barunga joins The KidsVinka Barunga has made history by becoming the first Aboriginal doctor from Derby and she's also added The Kids researcher to her list of achievements.
Improving the lives of children with a disability and their families sits at the core of our team.
Eight-year-old Mikayla is the miracle child her parents never thought they would have. They’d tried for seven years to have a baby, and when Mikayla was finally born they couldn’t contain their excitement or pride. The fact she had Down syndrome was secondary.
The Kids has a range of specialised expertise, tools, platforms and technology to undertake cutting-edge science.
Research
Cultures of HRV-C for investigations of pathogenesis in childrenAnthony Belinda Ingrid Kicic Hales Laing BSc (Hons) PhD BSc (Hons) PhD BSc PhD Rothwell Family Fellow; Head, Airway Epithelial Research Senior
Research
Antifungal use in children with acute leukaemia: state of current evidence and directions for future researchInvasive fungal disease (IFD) remains a common and serious complication in children treated for leukaemia. Antifungal prescription in children with leukaemia presents unique challenges, particularly due to variation in IFD risk between and within leukaemia treatment protocols, drug toxicities and interactions between antifungals and chemotherapeutic agents.
Research
Assessing the Impact of Pneumococcal Conjugate Vaccine Immunization Schedule Change From 3+0 to 2+1 in Australian Children: A Retrospective Observational StudyIn mid-2018, the Australian childhood 13-valent pneumococcal conjugate vaccine schedule changed from 3+0 to 2+1, moving the third dose to 12 months of age, to address increasing breakthrough cases of invasive pneumococcal disease (IPD), predominantly in children aged >12 months. This study assessed the impact of this change using national IPD surveillance data.